lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
223 rows where filing_period = "third_quarter", filing_year = 2015 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, income_amount, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1725366 | HOSPIRA, INC. d19b7cb7-90d5-4ea3-83e7-9751414b741d | 3T | HOSPIRA, INC. | 318711 | HOSPIRA INC | 2015 | third_quarter | PHA | Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94) | HOUSE OF REPRESENTATIVES,SENATE | 270000 | 0 | 1 | 2015-08-31T13:17:30.527000-04:00 | |
| 1725602 | RED+BLUE STRATEGIES d25f517f-5613-4316-90c3-92651ad3ead8 | 3T | RED+BLUE STRATEGIES | 400693064 | HOSPIRA | 2015 | third_quarter | PHA | Issues related to the naming of biosimilars as they enter into the national prescription drug marketplace. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 1 | 2015-09-09T15:21:43.843000-04:00 | |
| 1726164 | PRINTING INDUSTRIES OF AMERICA, INC. 7feada52-8d13-4f29-a047-b899b67f58b2 | 3A | PRINTING INDUSTRIES OF AMERICA, INC. | 32203 | PRINTING INDUSTRIES OF AMERICA INC | 2015 | third_quarter | PHA | Pharmaceutical Printed Literature | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Labor Relations Board (NLRB),Occupational Safety & Health Administration (OSHA),Securities & Exchange Commission (SEC),SENATE,U.S. Postal Service (USPS) | 105705 | 0 | 0 | 2015-10-01T13:00:14.633000-04:00 | |
| 1726680 | HOLLAND & KNIGHT LLP d12bf0d4-19de-456a-887f-7f607b0013f2 | Q3 | HOLLAND & KNIGHT LLP | 18466 | PROTECTING ACCESS TO PAIN RELIEF COALITION | 2015 | third_quarter | PHA | Advocating for policy to ensure patient access to pain relief. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-10-05T14:24:00.850000-04:00 | |
| 1727180 | AMERICAN COLLEGE OF CLINICAL PHARMACY 040accba-841d-4b31-9137-c049aa19fcfa | Q3 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2015 | third_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 127250 | 0 | 0 | 2015-10-07T14:56:58.347000-04:00 | |
| 1727634 | UNIVERSITY OF IOWA 1305704d-37e1-4d49-a12d-f4b228df1e6e | 3A | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2015 | third_quarter | PHA | Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals | Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT) | 86662 | 0 | 0 | 2015-10-09T10:35:55.577000-04:00 | |
| 1728000 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 082fe641-7a93-47c9-9610-7b27db8b3b04 | Q3 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 27478 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 2015 | third_quarter | PHA | H.R. 793 - Ensuring Seniors Access to Local Pharmacies Act of 2015; H.R. 244 - MAC Transparency Act of 2015; Congressional Oversight of 340 B Program; S. 1200 - Fairness to Pet Act Legislation 2015; S. 1190 -Ensuring Seniors Access to Local Pharmacies Act of 2015; S. 314 - Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 592 - Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 3174 - Fairness to Pet Owners Act of 2015; S. 1406 - Saving Access to Compounding Medications for Special Needs Patients Act | Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE | 575000 | 0 | 0 | 2015-10-09T16:14:30.907000-04:00 | |
| 1728119 | MR. VINCENT A. PANVINI 498f8805-54f9-4aef-ae96-c212394b1a4b | Q3 | MR. VINCENT A. PANVINI | 401008845 | PHRMA | 2015 | third_quarter | PHA | Trans-Pacific Partnership Patent Reform | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2015-10-10T16:43:02.910000-04:00 | ||
| 1728593 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. cf1bb936-0d1f-4080-aa69-584a3066c863 | Q3 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 4653 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 2015 | third_quarter | PHA | Proposals relating to the regulation of direct to consumer prescription drug advertising | HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 430000 | 0 | 0 | 2015-10-12T16:15:06.290000-04:00 | |
| 1728968 | ROCK & ASSOCIATES 8071eeff-b121-454d-a7cf-b3ebc57ea414 | Q3 | ROCK & ASSOCIATES | 33545 | BRAIDWOOD MANAGEMENT, INC. | 2015 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-10-13T10:53:59.250000-04:00 | |
| 1728972 | ROCK & ASSOCIATES 8e82ac35-026e-4aa0-84f9-27a2066b0d22 | Q3 | ROCK & ASSOCIATES | 33545 | DIAMONDBACK DRUGS | 2015 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-10-13T10:55:04.093000-04:00 | |
| 1728978 | ROCK & ASSOCIATES 3a5e5170-88a5-4b56-be4b-62b109c7f866 | Q3 | ROCK & ASSOCIATES | 33545 | VETERINARY PHARMACIES OF AMERICA, INC. | 2015 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-10-13T10:57:09.577000-04:00 | |
| 1728984 | ROCK & ASSOCIATES 0439e212-32f0-498a-8662-08ce5e53f355 | Q3 | ROCK & ASSOCIATES | 33545 | WEDGEWOOD VILLAGE PHARMACY, INC. | 2015 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-10-13T10:59:13.827000-04:00 | |
| 1728995 | ROCK & ASSOCIATES f303e540-49ca-418d-bca0-8b759948b02f | Q3 | ROCK & ASSOCIATES | 33545 | WOMEN'S INTERNATIONAL PHARMACY | 2015 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-10-13T10:59:19.017000-04:00 | |
| 1729004 | ROCK & ASSOCIATES 43e940e7-397b-4930-88d8-58bd2af38e16 | Q3 | ROCK & ASSOCIATES | 33545 | US COMPOUNDING | 2015 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-10-13T11:01:23.657000-04:00 | |
| 1729010 | ROCK & ASSOCIATES 578f1bfc-2d22-4dd2-b7ba-081bbca0a3d9 | 3A | ROCK & ASSOCIATES | 33545 | US COMPOUNDING | 2015 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2015-10-13T11:03:30.127000-04:00 | ||
| 1729017 | ROCK & ASSOCIATES da0391ae-6cf7-4694-9728-f2ddf7af3d0c | Q3 | ROCK & ASSOCIATES | 33545 | TOWN & COUNTRY COMPOUNDING AND CONSULTING | 2015 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2015-10-13T11:05:34.847000-04:00 | ||
| 1729020 | ROCK & ASSOCIATES c94c3dd5-98aa-401f-851e-082f00a9eac0 | Q3 | ROCK & ASSOCIATES | 33545 | WELLNESS PHARMACY | 2015 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-10-13T11:06:39.830000-04:00 | |
| 1729149 | THE STRATEGY GROUP, INC. 7c319583-128f-4f06-adcc-b93a2458f3db | Q3 | THE STRATEGY GROUP, INC. | 401103637 | PHRMA | 2015 | third_quarter | PHA | 340B Pharmacy Program. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-10-13T12:16:43.447000-04:00 | |
| 1729387 | PARRY, ROMANI, DECONCINI & SYMMS 271db916-c87d-4a1a-aaa5-75dc1b1d1801 | Q3 | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | ROCK & ASSOCIATES | 2015 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 22500 | 0 | 0 | 2015-10-13T14:28:39.243000-04:00 | |
| 1729690 | PARRY, ROMANI, DECONCINI & SYMMS 2b3f2776-1f93-4ee9-b4be-3e99393ef239 | 3A | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | ROCK & ASSOCIATES | 2015 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 21000 | 0 | 0 | 2015-10-13T16:38:35.633000-04:00 | |
| 1730345 | ACG ADVOCACY b211f9af-a9a2-4d5f-bf89-6fd0e803495e | Q3 | ACG ADVOCACY | 2057 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2015 | third_quarter | PHA | Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-10-14T12:58:27.127000-04:00 | |
| 1730626 | SANOFI US SERVICES INC. cf8c4aa2-b918-4273-b8b2-6a702e5ee770 | Q3 | SANOFI US SERVICES INC. | 56838 | SANOFI US SERVICES INC | 2015 | third_quarter | PHA | General issues related to the 340B Federal Drug Pricing Program | HOUSE OF REPRESENTATIVES,SENATE | 1170000 | 0 | 0 | 2015-10-14T14:15:42.777000-04:00 | |
| 1730628 | TCH GROUP, LLC bc30f584-d8d9-4eb0-99fe-62ae9026281d | Q3 | TCH GROUP, LLC | 51478 | CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) | 2015 | third_quarter | PHA | S.483, Ensuring Patient Access and Effective Drug Enforcement Act of 2015 | SENATE | 20000 | 0 | 0 | 2015-10-14T14:17:49.293000-04:00 | |
| 1731125 | KENT & O'CONNOR, INC. 2a404642-d0fb-42b7-ae6d-4d35d05258b4 | Q3 | KENT & O'CONNOR, INC. | 21426 | INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION | 2015 | third_quarter | PHA | Legislation and regulations relating to drug and safety issues. | Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),U.S. Customs & Border Protection | 30000 | 0 | 0 | 2015-10-15T09:33:41.560000-04:00 | |
| 1731184 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 84cd3189-42be-4296-b638-e123a18079c5 | Q3 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 35968 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015 | third_quarter | PHA | Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding. | Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE | 100000 | 0 | 0 | 2015-10-15T09:51:30.560000-04:00 | |
| 1731724 | THE D MAJOR GROUP 5d14e130-01ba-4f5d-ae33-7abeccddc49c | Q3 | THE D MAJOR GROUP | 401103162 | CVS CAREMARK | 2015 | third_quarter | PHA | Issues related to innovation in pharmacy delivery, including health information technology. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-10-15T12:21:29.187000-04:00 | |
| 1732122 | CHRISTY ELLERBEE CONSULTING, LLC 6a772079-e1e0-4638-98e6-2816aecd8015 | Q3 | CHRISTY ELLERBEE CONSULTING, LLC | 401103332 | INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.) | 2015 | third_quarter | PHA | H.R. 2872 Opioid Addiction Treatment Modernization Act. H.R. 1821 and S. 707 Opioid Overdose Reduction Act of 2015. H.R. 2536 and S. 1455 TREAT ACT. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2015-10-15T14:34:29.793000-04:00 | ||
| 1732231 | INDEPENDENT PHARMACY COOPERATIVE 43c7ed64-3998-4d19-ad1d-cef9a64b89b1 | Q3 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2015 | third_quarter | PHA | H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas. H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas. HR 6 21st Century Cures Act. IPC is not supportive of some of the "pay for" provisions. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2015-10-15T15:03:12.763000-04:00 | ||
| 1732454 | VALENTE & ASSOCIATES c69edfbb-2fb3-4166-8a76-68a8ebae0c7a | Q3 | VALENTE & ASSOCIATES | 45983 | SAV-MOR FRANCHISING, INC. | 2015 | third_quarter | PHA | Medicare Part D | HOUSE OF REPRESENTATIVES | 30000 | 0 | 0 | 2015-10-15T16:16:27.383000-04:00 | |
| 1732476 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 96987ac3-46ec-43fd-89df-cd48add4a3c5 | Q3 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2015 | third_quarter | PHA | Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives S. 1438 - Allowing Greater Access to Safe and Effective Contraception Act. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections S. 1532 - Affordability is Access Act. Clarifies that all oral contraceptive products be covered by insurance and provided to consumers without cost, regardless of prescription/nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 260000 | 0 | 0 | 2015-10-15T16:20:42.367000-04:00 | |
| 1732911 | NELSON MULLINS RILEY & SCARBOROUGH fd53c62c-fd5e-4f6c-9c76-32fc675f72f3 | Q3 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | CASCADE HEMOPHILIA CONSORTIUM | 2015 | third_quarter | PHA | Issues related to 340B Drug Pricing Progam | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-10-16T08:34:54.420000-04:00 | |
| 1732916 | NELSON MULLINS RILEY & SCARBOROUGH 1090f700-f9d1-42a5-a023-0402dd41fa41 | Q3 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | HEMOPHILIA OF GEORGIA | 2015 | third_quarter | PHA | Issues related to implementation of the ACA, Hemophilia research and treatments, and the 340B Drug Pricing Program | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-10-16T08:37:58.327000-04:00 | |
| 1732950 | WILLIAMS AND JENSEN, PLLC 7941b268-e180-4386-8d52-8ea2471feefe | Q3 | WILLIAMS AND JENSEN, PLLC | 41454 | FAGRON NORTH AMERICA | 2015 | third_quarter | PHA | Issues related to Drug Quality and Security Act (DQSA) and Pharmacy compounding. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-10-16T08:47:26.017000-04:00 | |
| 1733020 | AMERICAN VETERINARY MEDICAL ASSOCIATION 1bc29771-b831-417f-a5de-a6b763413d93 | 3A | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2015 | third_quarter | PHA | Guidance for Industry: Compounding Animal Drugs from Bulk Substances Discussions with Congressional staff, FDA and USDA regarding the use of antimicrobials in food-producing animals, particularly with respect to H.R.1552 (Preservation of Antibiotics for Medical Treatment Act), S. 621 (Preventing Antibiotic Resistance Act), and FDA's strategy (GRI #209 and VFD Rule) Discussions with Congressional staff, FDA and Government Accountability Office to express the need for compounding of medications for use in animals and FDA's draft GFI #230 Inquiries to, and discussions with, Congressional staff on veterinary pet prescriptions, particularly regarding H.R. 317/S. 1200, the Fairness to Pet Owners Act. | Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE | 220000 | 0 | 0 | 2015-10-16T09:05:14.283000-04:00 | |
| 1733025 | NELSON MULLINS RILEY & SCARBOROUGH ef8ec07d-9ce6-47d9-9332-e21ba6d76f4b | Q3 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.) | 2015 | third_quarter | PHA | Any legislation and regulation to the treatment of opioid abuse. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2015-10-16T09:08:18.190000-04:00 | |
| 1733039 | ALKERMES, INC. ce123943-bfb5-48ae-8ac4-c58ab1d13560 | Q3 | ALKERMES, INC. | 400458235 | ALKERMES, INC. | 2015 | third_quarter | PHA | Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 639/S 481, Improving Regulatory Transparency Act for New Medical Therapies Act | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) | 702000 | 0 | 0 | 2015-10-16T09:17:33.987000-04:00 | |
| 1733139 | RED+BLUE STRATEGIES 14084089-df2a-4b8f-9f26-ad483319bf3a | Q3 | RED+BLUE STRATEGIES | 400693064 | EXPRESS SCRIPTS INC. | 2015 | third_quarter | PHA | H.R.6 - 21st Century Cures - Issues related to exclusivity rights of certain prescription medications. Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. Issues related to the treatment of pharmacy benefit managers in federal programs. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Issues related to access and affordability for prescription medications for both government and private sector benefit programs. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-10-16T10:01:25.977000-04:00 | |
| 1733201 | RED+BLUE STRATEGIES c168b005-fb7f-423a-a485-eb74947e8340 | Q3 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2015 | third_quarter | PHA | H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars. Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies. CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks. Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. CMS call letter focused on changes in policies regarding mail order and pharmacy networks. Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars. Issues related to patents and the treatment of prescription medications. | Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-10-16T10:19:23.057000-04:00 | |
| 1733210 | RED+BLUE STRATEGIES 4f0e6c96-a63a-40ee-b5d7-72185e78fce7 | Q3 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2015 | third_quarter | PHA | H.R. 6 - 21st Century Cures Act - Issues related to ensuring that medically needed antibiotics are available to the public, curbing opioid abuse in Medicare Part D and maintaining the integrity of the federal Open Payments program. S. 1549 - The Care Planning Act - supporting advances in End-of-Life Care throughout the nation. Support of the inclusion of Advanced Care Planning codes in the CMS Physician Fee Schedule (PFS). S. 633 - The Promise for antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public. Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid. Advancing provisions to highlight Antibiotic Innovation in the President's FY 2016 budget. | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-10-16T10:23:32.760000-04:00 | |
| 1733367 | RED+BLUE STRATEGIES 73f6c2fe-09f2-4b09-b090-fdc424f6a51b | Q3 | RED+BLUE STRATEGIES | 400693064 | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS | 2015 | third_quarter | PHA | H.R. 6 - 21st Century Cures - Issues related to supporting programs to prevent opioid abuse in the Part D program. Issues related to opioid abuse. Issues related to state-based marketplaces. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-10-16T10:52:54.170000-04:00 | |
| 1733387 | COREWELL HEALTH 3f46ec53-7c59-4854-b2a5-4549748b8190 | Q3 | COREWELL HEALTH | 298455 | COREWELL HEALTH | 2015 | third_quarter | PHA | Discussions regarding value of 340B Pharmacy | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-10-16T10:55:07.030000-04:00 | |
| 1733423 | MERCURY PUBLIC AFFAIRS, LLC b9c1c7d4-64b6-4df1-907b-4b3327db98d5 | Q3 | MERCURY PUBLIC AFFAIRS, LLC | 70175 | KALISPELL REGIONAL HEALTHCARE | 2015 | third_quarter | PHA | Veteran pharmacy issues and polices | Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 30000 | 0 | 0 | 2015-10-16T11:05:52.580000-04:00 | |
| 1733503 | JOHNS HOPKINS UNIVERSITY d9ea2d39-5442-4ae0-bd30-7ecb6f38c32e | Q3 | JOHNS HOPKINS UNIVERSITY | 20664 | JOHNS HOPKINS UNIVERSITY | 2015 | third_quarter | PHA | Pharmaceutical drug price increases; 340B drug discount program | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2015-10-16T11:16:59.657000-04:00 | |
| 1733590 | RED+BLUE STRATEGIES 50d58cc8-6b91-4402-9033-a5f6606e9d89 | Q3 | RED+BLUE STRATEGIES | 400693064 | COHERUS BIOSCIENCES | 2015 | third_quarter | PHA | CMS Proposed Physician Fee Schedule(PFS) with a focus on provisions dealthing with the treatment of Medicare's reimbursement for a new class of prescription medications, Biosimilars. Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States. | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 20000 | 0 | 0 | 2015-10-16T11:32:18.847000-04:00 | |
| 1733758 | BLUESTONE STRATEGIES, LLC 1677813a-495f-4f35-bfea-429a0049595f | Q3 | BLUESTONE STRATEGIES, LLC | 400658980 | AMERICA'S HEALTH INSURANCE PLANS (AHIP) | 2015 | third_quarter | PHA | Specialty Drugs and Drug Pricing | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-10-16T11:59:41.037000-04:00 | |
| 1733809 | BLUESTONE STRATEGIES, LLC 91292c12-8e63-4675-91b6-9c8b7d72b7cb | Q3 | BLUESTONE STRATEGIES, LLC | 400658980 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2015 | third_quarter | PHA | Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues; HR 6, the 21st Century Cures Act; S. 1413, RX Abuse and Prevention; S.1913, Pharmacy Lock-In | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-10-16T12:11:38.667000-04:00 | |
| 1733827 | NOVO NORDISK INC. cc56ab2d-3c34-4444-a37b-f4379c4b421c | Q3 | NOVO NORDISK INC. | 284790 | NOVO NORDISK INC. | 2015 | third_quarter | PHA | P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 620000 | 0 | 0 | 2015-10-16T12:15:55.493000-04:00 | |
| 1733984 | CHAMBER HILL STRATEGIES b6734469-1758-46a7-a469-fede3c08630a | Q3 | CHAMBER HILL STRATEGIES | 400645947 | AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL) | 2015 | third_quarter | PHA | Implementation issues related to P.L. 113-54, the Drug Quality and Security Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-10-16T12:57:57.997000-04:00 | |
| 1734099 | ACADEMY OF MANAGED CARE PHARMACY 024ede9b-c346-49ac-84d5-d208110ab349 | Q3 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2015 | third_quarter | PHA | Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, supporting the reauthorization of the National All Schedules Prescription Electronic Reporting Act (S 480/HR 1725)and providing comments to CDC on opioid dispensing guidelines | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 210000 | 0 | 0 | 2015-10-16T13:30:08.783000-04:00 | |
| 1734224 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION cdc649ec-d291-4d3a-98b6-14a6629be6cb | 3A | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 31348 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2015 | third_quarter | PHA | Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including non-interference, pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care pharmacy, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Issues related to prescription drug abuse in Medicare. H.R.2 Medicare Access and CHIP Reauthorization Act of 2015 - provisions related to the expansion of availability of Medicare data H.R.244, The MAC Transparency Act H.R.793S1190, The Ensuring Seniors Access to Local Pharmacies Act H.R. 1021, The Protecting the Integrity of Medicare Act H.R.1600, The Patient Access to Treatments Act H.R. 804, The Access to Medicare Data Act H.R. 2298, The Medicare Drug Abuse Prevention Act H.R. 6, Century Cures Act | Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),General Services Administration (GSA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE | 622142 | 0 | 0 | 2015-10-16T13:58:28.803000-04:00 | |
| 1734937 | THE STRATEGY GROUP, INC. 22667963-b981-43ae-a62a-ea4537e8e2c5 | 3A | THE STRATEGY GROUP, INC. | 401103637 | PHRMA | 2015 | third_quarter | PHA | 340B Pharmacy Program. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-10-16T16:11:35.367000-04:00 | |
| 1735155 | THORSEN FRENCH ADVOCACY LLC 46eca8e3-35ad-41a0-880d-e0cdb646e9e6 | Q3 | THORSEN FRENCH ADVOCACY LLC | 400599826 | ASTRAZENECA PHARMACEUTICALS LP | 2015 | third_quarter | PHA | Issues related to access to pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2015-10-16T16:52:17.680000-04:00 | |
| 1735169 | SAFEWAY INC. affaadbe-5f52-4b03-9292-474f5f212786 | Q3 | SAFEWAY INC. | 300173 | SAFEWAY | 2015 | third_quarter | PHA | H.R. 592/S. 314 -- Pharmacy and Underserved Areas Enhancement Act, all provisions. Draft Proposal: Preserve Access to Community Pharmacies in TRICARE. | HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2015-10-16T16:54:30.403000-04:00 | |
| 1735372 | THE INGRAM GROUP LLC b097d107-4b34-4f8a-aaba-2151ff98c723 | Q3 | THE INGRAM GROUP LLC | 400577737 | ELI LILLY AND COMPANY | 2015 | third_quarter | PHA | S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2015. H.R.6, 21st Century Cures Act. General issues related to the biopharmaceutical and pharmaceutical industries. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2015-10-16T17:45:49.073000-04:00 | |
| 1735379 | THORSEN FRENCH ADVOCACY LLC fd6ba951-2497-4b11-86ef-5bde16298734 | Q3 | THORSEN FRENCH ADVOCACY LLC | 400599826 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2015 | third_quarter | PHA | Issues related to pharmaceutical market value. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-10-16T17:46:59.823000-04:00 | |
| 1736704 | FLYNN & ASSOCIATES, INC. ba7b39f4-28ed-4f59-85ba-9ae8aa1d7585 | Q3 | FLYNN & ASSOCIATES, INC. | 15020 | PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION | 2015 | third_quarter | PHA | Medicare Part-D rebates Trade agreements Patent reform legislation H.R. 9 | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-10-18T15:04:40.223000-04:00 | |
| 1736877 | EMPIRE CONSULTING GROUP 8647783b-df86-440e-bab8-c7c2466a2583 | Q3 | EMPIRE CONSULTING GROUP | 400703105 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2015 | third_quarter | PHA | Medicare Prescription Drug Act; HR 9, Innovation Act; 21st Century Cures Act; prescription drug costs; Trans Pacific Partnership (TPP) Agreement (provisions relating to data protection for biologics);and budget reconciliation legislation (provisions relating to healthcare). | HOUSE OF REPRESENTATIVES | 40000 | 0 | 0 | 2015-10-18T21:31:16.157000-04:00 | |
| 1737129 | NATIONAL RURAL HEALTH ASSOCATION 97c0afc4-8120-4b75-815e-113dbbdbfdc1 | Q3 | NATIONAL RURAL HEALTH ASSOCATION | 53048 | NATIONAL RURAL HEALTH ASSOCATION | 2015 | third_quarter | PHA | Support for 340B program | HOUSE OF REPRESENTATIVES,SENATE | 25924 | 0 | 0 | 2015-10-19T09:27:04.567000-04:00 | |
| 1737181 | ELI LILLY AND COMPANY ce05564f-2f31-45c1-8577-1e2f6a7bfa96 | Q3 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2015 | third_quarter | PHA | Hospital discounts; 340B Program | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 1630000 | 0 | 0 | 2015-10-19T09:42:52.927000-04:00 | |
| 1737199 | APOTEX CORP. 82670507-fcea-4733-83cc-bc98e74a9569 | Q3 | APOTEX CORP. | 310973 | APOTEX CORP. | 2015 | third_quarter | PHA | HR 6, The 21st Century Cures Act, provisions relating to the discovery, approval and manufacturing of pharmaceuticals; Federal policy relating to issues affecting the generic drug industry within the Senate Health, Education, Labor and Pensions Committee's Innovation for Healthier Americans initiative; HR 2841, The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; S 1137, The FAIR Generics Act, provisions relating to market blockages caused by "parked" 180 day exclusivity periods; S. 2109, The Preserve Access to Affordable Generics Act, provisions relating to the legality of patent settlements between brand and generic pharmaceutical companies; Federal policy relating to the implementation of the Biologic Price Competition and Innovation Act, Title VII, Subtitle A, of Public Law 111-148, The Patient Protection and Affordable Care Act; and FDA proposed rule, Designation of Official Names for Certain Biological Products, Docket No. FDA-2015-N-0648, provisions related to nonproprietary naming for biologic products | HOUSE OF REPRESENTATIVES,SENATE | 130000 | 0 | 0 | 2015-10-19T09:46:02.460000-04:00 | |
| 1737297 | PRIME POLICY GROUP 83d2cbf4-6a41-4584-b21d-d5d769771378 | Q3 | PRIME POLICY GROUP | 400532589 | GLAXOSMITHKLINE | 2015 | third_quarter | PHA | Vaccines Drug Pricing | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 40000 | 0 | 0 | 2015-10-19T10:14:52.837000-04:00 | |
| 1737555 | GILEAD SCIENCES, INC. 12e22244-1ab3-44e0-8945-ff0a0b800bcb | Q3 | GILEAD SCIENCES, INC. | 287177 | GILEAD SCIENCES INC | 2015 | third_quarter | PHA | Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; Issues related to coverage and reimbursement of pharmaceuticals; Issues related to Medicare, Medicaid and Affordable Care Act implementation; and FDA issues and 340B. | Commerce, Dept of (DOC),Defense, Dept of (DOD),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Veterans Affairs, Dept of (VA) | 700000 | 0 | 0 | 2015-10-19T11:02:49.813000-04:00 | |
| 1737921 | TEVA PHARMACEUTICALS USA, INC. 7e993854-227b-47d1-9b8b-f9aa102aba33 | Q3 | TEVA PHARMACEUTICALS USA, INC. | 76695 | TEVA PHARMACEUTICALS USA INC | 2015 | third_quarter | PHA | Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR) | 990000 | 0 | 0 | 2015-10-19T11:41:47.833000-04:00 | |
| 1738109 | AMERICAN PHARMACISTS ASSOCIATION 678e999e-79d7-45d1-9249-81fa0066b709 | Q3 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2015 | third_quarter | PHA | Reimbursement of pharmacist services - HR592/S314 Transitions of care Risk evaluation and mitigation services Track and trace/supply chain Health information technology Immunizations Compounding Tele-medicine Quality rating AMP FULs Biosimiliars Drug importation Generics labeling Preferred pharmacy network - HR793 Electronic labeling Home infusion - HR605/S275 21st century cures Drug Disposal | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) | 27243 | 0 | 0 | 2015-10-19T12:00:04.743000-04:00 | |
| 1738267 | WALTER CONSULTING 9373b789-58e9-4e51-af0d-7973386e7b3d | Q3 | WALTER CONSULTING | 301697 | AMERISOURCEBERGEN CORPORATION | 2015 | third_quarter | PHA | H.R. 471, the Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S.483, The Regulatory Transparency, Patient Access and Effective Drug Enforcement Act | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2015-10-19T12:18:48.027000-04:00 | |
| 1738345 | BLUECROSS BLUESHIELD OF TENNESSEE 97b8847e-e8ab-407e-ad4d-be90dbe684fa | Q3 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2015 | third_quarter | PHA | General Pharmacy Issues; HR6, 21st Century Cures; opioid abuse; specialty drug pricing | Equal Employment Opportunity Commission (EEOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-10-19T12:29:24.557000-04:00 | |
| 1738446 | BROWN RUDNICK LLP eeca671d-79d1-4922-922c-de976a83089d | Q3 | BROWN RUDNICK LLP | 287895 | HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC | 2015 | third_quarter | PHA | Issues relating to Implementation of P.L. 113 - 54 (Drug Quality and Security Act); H.R. 471 & S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 480, H.R. 1725-relating to Prescription Drug Monitoring Programs; S. 524 & H.R. 953 relating to prescription drug abuse | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-10-19T12:46:02.123000-04:00 | |
| 1738753 | HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY dfeae908-27b0-40c4-9414-93f9630a89dc | Q3 | HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY | 72793 | HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY | 2015 | third_quarter | PHA | Pharmaceutical Innovation; Patent Reform; Senate HELP Cures Bill information | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-10-19T13:20:14.047000-04:00 | |
| 1738800 | WAXMAN STRATEGIES 0eedd3b2-3d68-4f15-8282-12e124adba62 | Q3 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2015 | third_quarter | PHA | Laws and regulations affecting the 340B Drug Discount Program | Health & Human Services, Dept of (HHS) | 18750 | 0 | 0 | 2015-10-19T13:26:03.080000-04:00 | |
| 1738806 | KAISER FOUNDATION HEALTH PLAN INC. 5c0de7bc-e77a-4e2e-8219-dbe29ab131c3 | Q3 | KAISER FOUNDATION HEALTH PLAN INC. | 21027 | KAISER FOUNDATION HEALTH PLAN INC | 2015 | third_quarter | PHA | S 1137 - PATENT Act, Protecting American Talent and Entrepreneurship Act of 2015: A bill to amend title 35, United States Code, and the Leahy-Smith America Invents Act to make improvements and technical corrections, and for other purposes. Grassley (R-IA) | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 140000 | 0 | 0 | 2015-10-19T13:27:05.190000-04:00 | |
| 1738955 | SLC HEALTH STRATEGIES, LLC 93613ec1-795a-4338-967c-53334ee617ad | Q3 | SLC HEALTH STRATEGIES, LLC | 401018877 | NOVO NORDISK PHARMACEUTICALS, INC. | 2015 | third_quarter | PHA | HR 6 - 21st Century Cures Act FDA issues regarding biosimilar products; 340B program matters | HOUSE OF REPRESENTATIVES,SENATE | 22500 | 0 | 0 | 2015-10-19T13:45:27.897000-04:00 | |
| 1739104 | ISEMAN & ASSOCIATES LLC c18877d8-ea88-4d24-be52-88bb0c9c7327 | Q3 | ISEMAN & ASSOCIATES LLC | 401103582 | TICHENOR VENTURES, LLC | 2015 | third_quarter | PHA | Monitoring biotech legislation | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-10-19T13:59:48.100000-04:00 | |
| 1739236 | BROWN RUDNICK LLP 4fd866db-a7ee-4f0e-99cf-cab0e8b014e8 | Q3 | BROWN RUDNICK LLP | 287895 | PRIME THERAPEUTICS | 2015 | third_quarter | PHA | HR 793 - Ensuring Seniors Access to Local Pharmacies Act | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-10-19T14:10:52.757000-04:00 | |
| 1739262 | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 4db32106-d1ca-489e-8c47-b8deefd2dc31 | Q3 | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. | 6382 | BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | 2015 | third_quarter | PHA | Pharmaceutical innovation and patent reform H.R. 6 - Introduced May 19, 2015 by Rep. Fred Upton, The 21st Century Cures Act Provisions related to bringing medical treatments to market faster with monies allocated to Medicare Part D Reinsurance | HOUSE OF REPRESENTATIVES,SENATE | 178269 | 0 | 0 | 2015-10-19T14:13:19.803000-04:00 | |
| 1739311 | BROWN RUDNICK LLP 201231ef-fd99-4117-94b4-670d042f26d3 | Q3 | BROWN RUDNICK LLP | 287895 | AMNEAL PHARMACEUTICALS | 2015 | third_quarter | PHA | Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); Issues relating to abuse deterrent drug development | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2015-10-19T14:17:07.727000-04:00 | |
| 1739340 | BROWN RUDNICK LLP 1e9c1249-d712-4a53-a4e9-6bbc4bb0319a | Q3 | BROWN RUDNICK LLP | 287895 | EXELA HOLDINGS, LLC | 2015 | third_quarter | PHA | Issues relating to ANDA review and approval | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-10-19T14:18:26.507000-04:00 | |
| 1739364 | BROWN RUDNICK LLP f8d37404-96ee-430d-a336-9e05fe530101 | Q3 | BROWN RUDNICK LLP | 287895 | ZYDUS PHARMACEUTICALS USA INC. | 2015 | third_quarter | PHA | Issues relating to generic drug pricing | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-10-19T14:20:43.507000-04:00 | |
| 1739412 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 51189100-5076-445f-8938-2232e6bf3248 | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL ASSOCIATION OF EPILEPSY CENTERS | 2015 | third_quarter | PHA | Issues related to anti-epileptic drugs. | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 10000 | 0 | 0 | 2015-10-19T14:24:26.587000-04:00 | |
| 1739426 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 411eb8dd-ee10-458a-9f21-a36647cad96d | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | AMERICAN SOCIETY OF HEMATOLOGY | 2015 | third_quarter | PHA | HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 30000 | 0 | 0 | 2015-10-19T14:25:37.290000-04:00 | |
| 1739467 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. f0b98046-869f-4cdd-8474-5d744384b069 | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL HEMOPHILIA FOUNDATION | 2015 | third_quarter | PHA | Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. HR 1600, Patients Access to Treatment Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE | 50000 | 0 | 0 | 2015-10-19T14:26:55.820000-04:00 | |
| 1739520 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 6098c223-8865-453c-baed-26ff08cd7666 | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | THE HEMOPHILIA ALLIANCE | 2015 | third_quarter | PHA | issues related to the 340B drug discount program; HR 6, 21st Century Cures potential amendment | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-10-19T14:29:21.603000-04:00 | |
| 1739669 | KOUNTOUPES DENHAM CARR & REID, LLC b5765f8e-d9c3-4206-b040-17f35a978801 | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2015 | third_quarter | PHA | General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. Issues related to H.R. 6, "21st Century Cures" as well as FDA and NIH modernization. Draft legislation regarding microbeads in over the counter products; Issues related to the over the counter drug monograph process. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-10-19T14:40:11.557000-04:00 | |
| 1739759 | UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY 4e6ebef7-0694-4508-baa9-5ad14f4dc9ff | Q3 | UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY | 401097063 | UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY | 2015 | third_quarter | PHA | 340B Program support to maintain current level of funding and discounts | Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 30271 | 0 | 0 | 2015-10-19T14:49:19.120000-04:00 | |
| 1739852 | FTI GOVERNMENT AFFAIRS d065d905-cca3-4e2f-a787-0fc5f4d51ed2 | Q3 | FTI GOVERNMENT AFFAIRS | 401054971 | PERRIGO, INC. | 2015 | third_quarter | PHA | Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2015-10-19T14:57:34.590000-04:00 | |
| 1739927 | ANIMAL HEALTH INSTITUTE 7b090eb9-8706-47c5-88eb-6f2390f28379 | Q3 | ANIMAL HEALTH INSTITUTE | 4037 | ANIMAL HEALTH INSTITUTE | 2015 | third_quarter | PHA | Issues related to illegal drug manufacturing under the guise of pharmacy compounding; Issues related to the granting of Categorical Exclusions from Environmental Assessments for animal health products; HR 3174 and S 1200 - Fairness to Pet Owners Act | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2015-10-19T15:01:18.483000-04:00 | |
| 1739961 | FOLEY & LARDNER LLP 5167e925-b315-4881-808c-8612b7440e5e | Q3 | FOLEY & LARDNER LLP | 15042 | PAR PHARMACEUTICAL | 2015 | third_quarter | PHA | FDA issues | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-10-19T15:02:42.920000-04:00 | |
| 1740287 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 09ec1c96-66fd-489a-9653-7e38edada480 | Q3 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2015 | third_quarter | PHA | Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact with GAO on pharmacy compounding. | Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 250000 | 0 | 0 | 2015-10-19T15:29:39.500000-04:00 | |
| 1740492 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) a6396ba9-47cb-4949-878d-0d5aa337efb2 | Q3 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2015 | third_quarter | PHA | Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483, S. 524, H.R. 953); 21st Century Cures (H.R. 6); Importation of Prescription Drugs (S. 122, H.R. 2228) | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 309992 | 0 | 0 | 2015-10-19T15:41:54.360000-04:00 | |
| 1741004 | MR. GALEN RESER a129ab7f-b1f8-4a3e-b6fa-ae7b54c17fc0 | Q3 | MR. GALEN RESER | 401055978 | PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS) | 2015 | third_quarter | PHA | Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-10-19T16:12:31.270000-04:00 | |
| 1741082 | ALLERGAN USA, INC. fb6de475-63ea-4241-900a-24aed77d7f88 | Q3 | ALLERGAN USA, INC. | 63837 | ALLERGAN USA, INC. | 2015 | third_quarter | PHA | Drug Labeling Drug Importation Track and Trace | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Patent & Trademark Office (PTO),SENATE | 850000 | 0 | 0 | 2015-10-19T16:17:13-04:00 | |
| 1741607 | WEST FRONT STRATEGIES LLC 5fb5a2c8-97dd-4b08-9304-3a6cbec3ae90 | Q3 | WEST FRONT STRATEGIES LLC | 401103493 | WALGREEN CO. | 2015 | third_quarter | PHA | Pharmacy and Medically Underserved Areas Enhancement Act (S. 314 and HR 592), to amend Title IIX of the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved areas. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-10-19T16:52:33.543000-04:00 | |
| 1741788 | CAPITOL HILL CONSULTING GROUP c3cfefb8-88c8-470c-b174-a91ace0256e6 | Q3 | CAPITOL HILL CONSULTING GROUP | 72053 | ENDO PHARMACEUTICALS | 2015 | third_quarter | PHA | Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825 | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-10-19T17:05:38.183000-04:00 | |
| 1742101 | THE SIMMONS & RUSSELL GROUP, LLC 51691d0b-9a3b-4c01-bb1f-925d6ca7a9d8 | Q3 | THE SIMMONS & RUSSELL GROUP, LLC | 401103235 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2015 | third_quarter | PHA | Drug importation and the FAIR Generics legislation; An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025, S.CON.RES.11. | SENATE | 60000 | 0 | 0 | 2015-10-19T17:35:40.173000-04:00 | |
| 1742109 | GREATER NEW YORK HOSPITAL ASSOCIATION 3bef94f8-3a08-4880-b19a-307a1c9ac723 | Q3 | GREATER NEW YORK HOSPITAL ASSOCIATION | 16830 | GREATER NEW YORK HOSPITAL ASSOCIATION | 2015 | third_quarter | PHA | Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price "gag clauses"; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; support reforming the durable medical equipment competitive bidding program; supporting "any willing pharmacy" legislation; promoting access to biosimilars (labeling/interchangeability); 21st Century Cures Act (H.R.6) - general support for overall bill, support final pharmacy lock-in policy, oppose PPSA weakening of existing requirements, oppose Section 4004 treatment of infusion drugs furnished through durable medical equipment; Ensuring Seniors Access to Local Pharmacies Act (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (H.R.592/S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Empowerment Act (S.776) - support; Strengthening Medicare Advantage Through Innovation and Transparency for Seniors - oppose; FDA-2014-D-1524-0002 - comments, Administration and Capitol Hill meetings on draft guidance on repackaging of certain human drug products by pharmacies and outsourcing facilities; FDA-2014-N-1459 - comments on draft MOU addressing certain distributions of compounded human drug products between states and the FDA; proposed changes to the 340B prescription drug program - oppose; 21st Century Cures Act (H.R.6) - support; proposed amendments to 340b program (not ultimately included in H.R.6) - oppose; provide comments on proposed 340b omnibus guidance (RIN 0906 AB08). | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office | 300000 | 0 | 0 | 2015-10-19T17:36:43.220000-04:00 | |
| 1742376 | EXPRESS SCRIPTS, INC. 174172a0-a514-4853-8273-f9cfb0ccfbdc | Q3 | EXPRESS SCRIPTS, INC. | 294416 | EXPRESS SCRIPTS, INC. | 2015 | third_quarter | PHA | Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600. | Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Personnel Management (OPM),SENATE,White House Office | 520000 | 0 | 0 | 2015-10-19T18:06:50.377000-04:00 | |
| 1742485 | KING & SPALDING LLP 4c6e81cd-c801-4f8e-a94b-a059e3486410 | Q3 | KING & SPALDING LLP | 21632 | SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) | 2015 | third_quarter | PHA | Issues related to inclusion of prescription drugs within Essential Health Benefit; H.R. 2646, Helping Families in Mental Health Crisis Act of 2015; S. 1945, Mental Health Reform Act of 2015; and mental health coverage expansion | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-10-19T18:29:00.380000-04:00 | |
| 1742491 | OREGON HEALTH & SCIENCE UNIVERSITY 68711fb7-8ec7-45b0-beae-99edbe714b68 | Q3 | OREGON HEALTH & SCIENCE UNIVERSITY | 30291 | OREGON HEALTH & SCIENCE UNIVERSITY | 2015 | third_quarter | PHA | 340b Drug Discount Program for safety net hospitals. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2015-10-19T18:29:04.693000-04:00 | |
| 1743004 | BLUE CROSS AND BLUE SHIELD ASSOCIATION f17abd42-c621-4b9c-8fa6-31e6aec87b86 | Q3 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 6358 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 2015 | third_quarter | PHA | Pharmaceutical Innovation; Patent Reform; HELP Cures Bill Information | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,Treasury, Dept of,White House Office | 2110000 | 0 | 0 | 2015-10-19T22:03:24.853000-04:00 | |
| 1743388 | BRAVO GROUP 5c7d7163-df4c-47e5-941b-7e284fdd9f3a | Q3 | BRAVO GROUP | 296293 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2015 | third_quarter | PHA | Biopharmaceutical issues including colon, social and economic, value of the biopharmaceutical sector, patient access and safety issues, life science innovation, and job impact. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-10-20T08:14:55.040000-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);